Therapeutics
Exploring the latest in Therapeutics.
Therapeutics
Drug Therapy Development Explained: 5 Stages, Costs, Timelines, and the New AI-Driven R&D Shift
Therapeutics
The Fast Track Paradox: Unpacking Clinical Development Times for FDA-Approved Drugs (2010–2020)
Therapeutics
The Hidden Cost of Failure: How Basic Biological Research Can Reshape Drug Therapy Development
Therapeutics
Drug Therapy Development Trends: Insights from 20 Volumes of 'Drug Design, Development and Therapy'
Therapeutics
Navigating the Complexities of CNS Drug Development: From Animal Models to Human-Centric Strategies
Therapeutics
Beyond Fixed Dosing: The Drug Titration Paradox and the Case for Personalized Medicine Strategies
Therapeutics
The Billion-Dollar Pipeline: Unpacking the Economic and Strategic Logic of Modern Drug Development
Therapeutics
From Omics to AI: The Evolving Economic and Technological Architecture of Cancer Drug Development
Therapeutics
Beyond the Lab Bench: The Invisible Supply Chain Logic Reshaping Drug Therapy Development
Therapeutics
The Crushing Economics of Alzheimer’s Drug Development: Why 100% Failure Rates Signal a Systemic Crisis
Therapeutics
The 12% Reality: Unpacking the Economic and Strategic Logic Behind Drug Development Phases
Therapeutics
Roche's Pipeline Pivot: Navigating Biosimilar Erosion with a Dual Bet on Cancer and Obesity
Therapeutics
Beyond the 65% Surge: How Nektar's Rezpegaldesleukin Could Reshape the Alopecia Areata Treatment Paradigm
Therapeutics
Beyond mRNA and Gene Therapy: How Serif's 'Modified DNA' Aims to Redefine Biotech's Next Frontier
Therapeutics
Beyond the Headline: The Strategic Significance of Erica Schwartz's Appointment to Lead the CDC
Therapeutics
Biotech's Pivot: Workforce Cuts, Asset Reacquisitions & Leadership Shifts Signal Industry Realignment
Therapeutics
Beyond Weight Loss: How Eli Lilly's Orforglipron Heart Safety Data Reshapes the Obesity Drug Market
Therapeutics
Beyond the Merger: How Obsidian's Reverse Takeover Signals a New Era for Financially-Strapped Biotechs
Therapeutics
Beyond the $1.2B Deal: How UCB's Neurona Acquisition Signals a Paradigm Shift in Epilepsy Treatment
Therapeutics
Beyond the Deal: How Eli Lilly's CrossBridge Bio Acquisition Reveals the New ADC Arms Race
Therapeutics
Beyond Stelara: How Johnson & Johnson's Q1 2026 Reveals a Strategic Pivot in Pharma's Post-Blockbuster Era
Therapeutics
Beyond the Rash: The Hidden Design Flaws Dooming Dermatology Drug Trials and How to Fix Them
Therapeutics
Beyond the $77M: How Crossbow's Series B Signals a Strategic Pivot in T-Cell Engager Therapeutics
Therapeutics
Beyond the Pill: How J&J's Oral Psoriasis Drug Icotyde Signals a Strategic Shift in Autoimmune Therapeutics
Leveraging the success of pandemic vaccines, researchers are now repurposing mRNA platforms to develop personalized cancer treatments and therapies for rare diseases.